Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

A Reminder App to Optimize Bladder Filling in Patients with Prostate Cancer Receiving HYPO-fractionated Radiotherapy

NCT06784115 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2025-02-15
Last updated
2025-01-20

Condition(s) studied

Prostate Cancer Patients Treated by Radiotherapy

Investigational drug(s) / intervention(s)

Reminder App

Reminder App: The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.

Study summary

The primary goal of this study is to assess the impact of an app that reminds patients treated with hypofractionated radiotherapy (HF-RT) for prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes \<200 ml during the HF-RT course and to demonstrate that this number is lower than without using an app (historical control group).

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Histologically proven prostate cancer 2. Indication for definitive HF-RT 3. Possession of and ability to use a smartphone 4. Bladder volume at CT-simulation \<200 ml 5. Male gender 6. Age ≥18 years 7. Written informed consent 8. Capacity of the patient to contract Exclusion Criteria: 1. Radiotherapy of pelvic lymph nodes 2. Expected non-compliance

Primary outcome measure(s)

  • Number of fractions with bladder volumes <200 ml at the end of the radiotherapy course — through study completion, an average of 4 weeks
    The primary endpoint is the number of radiation fractions with bladder volumes \<200 ml at the end of the radiotherapy course. The bladder volume at each radiation fraction is calculated from the corresponding Cone-Beam Computed Tomography (CBCT).

Trial sites (4)

FacilityCityRegionStatus
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark Vejle Southern Denmark
Medical Practice for Radiotherapy and Radiation Oncology Hanover Lower Saxony
Department of Radiation Oncology, University of Lübeck and University Medical Center Schleswig-Holstein Lübeck Schleswig-Holstein
Radiation Oncology Department, Hospital Universitario Cruces/Biobizkaia Health Research Institute University of the Basque Country Barakaldo Basque Country
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06784115 on ClinicalTrials.gov ↗ ← All trials in Denmark